Olio Labs vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI drug discovery company identifying multi-protein combination therapeutics 4x faster at 90% lower cost; YC S23 $4.5M Boom Capital Series A with in vivo/vitro results competing with Recursion for combination therapy AI.
About
Olio Labs is a San Francisco-based computational drug discovery company using AI and machine learning to identify multi-protein combination therapeutics for complex diseases — targeting biological pathways where single-target drugs fail because the disease involves multiple protein interactions simultaneously. Founded in 2023 and backed by Y Combinator (S23) with $5 million raised including a $4.5 million Series A led by Boom Capital and Overwater Ventures in March 2025, Olio Labs' combination therapeutics platform has demonstrated in vivo and in vitro superiority over existing market drugs, with a discovery process claimed to be 4x faster and 90% lower cost than traditional drug development approaches.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.